Germans win battle for AAH
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.BY MAGNUS GRIMOND
The German pharmaceuticals group GEHE yesterday emerged victorious in its £400m battle for control of AAH, Britain's leading drugs wholesaler.
But the bid was thrown into some confusion almost as soon as GEHE declared its offer "unconditional as to acceptances" after winning the backing of owners of close to 65 per cent of the shares.
Despite the clear majority in favour, AAH said it could not advise shareholders to accept the 445p a share offer as GEHE was unable to say its offer was unconditional in all respects until the board of its UK subsidiary had met. Technically, the bidder could allow the offer to lapse if the detailed legal conditions of the bid had not been met, although advisers admitted that the possibility was pretty remote.
As expected, AAH's two big institutional shareholders, PDFM with 17 per cent of the shares, and Schroders, holding between 7 and 8 per cent, tipped the balance by accepting the offer. As a result, GEHE ended up with acceptances for 35.13 per cent of AAH's shares. With the 29.20 per cent acquired during the offer and 0.64 per cent held before, that gave it a total of 64.97 per cent.
Dieter Kammerer, chairman of GEHE, said he was "delighted" that so many shareholders had recognised the merits of the offer. The AAH board said it would be writing to shareholders once the GEHE UK directors had met.
Yesterday's news came as Bilton, a property development company, announced that it had entered into an agreement with AAH Pharmaceuticals to construct a new 69,000 square foot distribution warehouse at Ruislip, Middlesex.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments